ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
11 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
117
|
30K
|
11
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
5 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
117
|
30K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
11 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
117
|
30K
|
11
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
793 |
274K |
15 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
793
|
274K
|
15
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
793 |
274K |
7 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
793
|
274K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bioshares 18th Biotech Summit Presentation
|
|
ma420
|
10 |
3.5K |
0 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
10
|
3.5K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bioshares 18th Biotech Summit Presentation
|
|
ma420
|
10 |
3.5K |
5 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
10
|
3.5K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
7 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
117
|
30K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
7 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
117
|
30K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
390 |
164K |
9 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
390
|
164K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
390 |
164K |
6 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
390
|
164K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
4 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
117
|
30K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
390 |
164K |
48 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
390
|
164K
|
48
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
390 |
164K |
21 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
390
|
164K
|
21
|
|
ASX - By Stock
|
SNT |
Re:
SNT - Research & Valuation
|
|
ma420
|
24 |
4.0K |
4 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
24
|
4.0K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
6
|
|
ASX - By Stock
|
SNT |
SNT - Research & Valuation
|
|
ma420
|
24 |
4.0K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
24
|
4.0K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
80K |
12 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
80K
|
12
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
7 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
8 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
8
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
7 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
10 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
10
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
16 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
16
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
6
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
62 |
25K |
0 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
62
|
25K
|
0
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation
|
|
ma420
|
43 |
10K |
4 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
43
|
10K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
9 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
9
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
62 |
25K |
1 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
62
|
25K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
30K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Company Analysis - Morgans
|
|
ma420
|
19 |
8.3K |
18 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
19
|
8.3K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
80K |
14 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
80K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Company Analysis - Morgans
|
|
ma420
|
19 |
8.3K |
4 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
19
|
8.3K
|
4
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
7.0K |
4 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
7.0K
|
4
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
7.0K |
1 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
7.0K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
10 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
117
|
30K
|
10
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
6 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
117
|
30K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
80K |
16 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
80K
|
16
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
7.0K |
0 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
7.0K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor Briefings & Webinar Notice
|
|
ma420
|
81 |
23K |
13 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
81
|
23K
|
13
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
4 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
30K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
5 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
30K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
1 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
30K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
3 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
30K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
765K |
4 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
2.2K
|
765K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
765K |
15 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
2.2K
|
765K
|
15
|
|
ASX - By Stock
|
COV |
Re:
Cleo Media Thread
|
|
ma420
|
9 |
3.7K |
2 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
9
|
3.7K
|
2
|
|